Isomorphic Labs: Funding, Investors & Team (Sep 2026)

Isomorphic Labs is an AI-first drug design and development company that transforms drug discovery by using machine learning to design and evaluate new medicines. It builds on research from DeepMind, including the AlphaFold system, which is used to predict protein structures and understand how biological molecules interact. The company develops AI models that simulate biological processes and support the design of drug candidates across multiple disease areas. Its platform integrates predictive and generative AI systems to explore chemical space, identify therapeutic targets, and propose new molecular structures with potential medical applications. It collaborates with pharmaceutical companies on research programs in areas such as oncology and immunology, with the aim of accelerating early-stage drug discovery and improving candidate selection. The organization also develops internal pipelines of AI-designed drug candidates and is progressing toward clinical testing of its first programs. Its work combines computational biology, medicinal chemistry, and machine learning to support end-to-end drug design workflows, from target identification to preclinical evaluation.

Isomorphic Labs has raised $2.1B across 1 round on record. The most recent is a Series B of $2.1B announced in May 2026.

Isomorphic Labs' most recent funding round on record is a Series B of $2.1B, announced in May 2026.

FundedIQ lists Demis Hassabis (Founder) at Isomorphic Labs.

Isomorphic Labs is based in London, England, United Kingdom.

Isomorphic Labs is in the 251-500 employee band.

Isomorphic Labs' latest round of $2.1B is above the $5.5M median round size for Artificial Intelligence companies on FundedIQ across 7,233 tracked companies over the last two years.